More than half of patients with Parkinson’s disease who consume cannabis have found it to be beneficial, according to a German survey.
Over eight percent of patients with Parkinson’s disease reported using cannabis products and more than half of those (54 percent) reported a beneficial clinical effect, according to results published in the Journal of Parkinson’s Disease.
Cannabis products containing THC can be prescribed in Germany when previous therapies are unsuccessful or not tolerated, and where cannabis can be expected with not a very unlikely chance to relieve disabling symptoms.
CBD is available without a prescription from pharmacies and on the internet.
“Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” explained lead investigator Prof Carsten Buhmann, Department of Neurology at the University Medical Center Hamburg-Eppendorf.
“PD patients fulfilling these criteria are entitled to be prescribed medical cannabis, but there are few data about which type of cannabinoid and which route of administration might be promising for which PD patient and which symptoms.
“We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result.”
Investigators assessed patient perceptions of medicinal cannabis, as well as evaluate the experiences of patients already using cannabis products.
They performed a nationwide, questionnaire-based survey among members of the German Parkinson Association, the largest consortium of Parkinson’s patients in German-speaking countries with nearly 21,000 members.
Over 1,300 questionnaires were analysed, with results showing that interest in medical cannabis among the Parkinson’s community was high, but knowledge about different types of products was limited.
Fifty-one percent of respondents were aware of the legality of medicinal cannabis, and 28 percent were aware of the various routes of administration (inhaling versus oral administration), but only nine percent were aware of the difference between THC and CBD.
Over 40 percent of users reported that it helped manage pain and muscle cramps, and more than 20 percent of users reported a reduction of stiffness, freezing, tremor, depression, anxiety, and restless legs.
Patients reported that inhaled cannabis products containing THC were more efficient in treating stiffness than oral products containing CBD, but were slightly less well tolerated.
Patients using cannabis tended to be younger, living in large cities and more aware of the legal and clinical aspects of medicinal cannabis.
Sixty-five percent of non-users were interested in using medicinal cannabis, but lack of knowledge and fear of side effects were reported as main reasons for not trying it.
“Our data confirms that Parkinson’s disease patients have a high interest in treatment with medicinal cannabis but lacked knowledge about how to take it and especially the differences between the two main cannabinoids, THC and CBD,” noted Prof Buhmann.
“Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis.
“The data reported here may help physicians decide which patients could benefit, which symptoms could be addressed, and which type of cannabinoid and route of administration might be suitable.”
He concluded: “Cannabis intake might be related to a placebo effect because of high patient expectations and conditioning, but even that can be considered as a therapeutic effect. It has to be stressed, though, that our findings are based on subjective patient reports and that clinically appropriate studies are urgently needed.”
Bastiaan R Bloem, MD, PhD, director of the Radboudumc Center of Expertise for Parkinson & Movement Disorders and co-editor-in chief of the Journal of Parkinson’s Disease, added: “These findings are interesting in that they confirm a widespread interest among patients in the use of cannabis as a potential treatment for people living with Parkinson’s disease.
“It is important to emphasise that more research is needed before cannabis can be prescribed as a treatment, and that guidelines currently recommend against the use of cannabis, even as self-medication, because the efficacy is not well established, and because there are safety concerns (adverse effects include among others sedation and hallucinations).
“As such, the present paper mainly serves to emphasise the need for carefully controlled clinical trials to further establish both the efficacy and safety of cannabis treatment.”
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure